T-ob/bcp particle/gelma composite
T-ob/bcp particle/gelma composite has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Jul 27, 2026: “Tideglusib-Preactivated Osteoblasts Encapsulated in Ceramic Particle-Reinforced GelMA Hydrogel for Enhanced Critical-Size Bone Defect Regeneration”.
1 paper studies it2 findingsUpdated
See all 1 papers on t-ob/bcp particle/gelma composite
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Animals1
What did studies of t-ob/bcp particle/gelma composite find?
2Studies of t-ob/bcp particle/gelma composite measured 2 outcomes: critical-size bone defects and bone mineral density.
Critical-size bone defects
downin rats1
1 study
Critical-size bone defects
downin rats1
T-ob/bcp particle/gelma composite decreases critical-size bone defects in rats (3.5 mm femoral defect) (>70% new bone area fraction).
“Histology showed more mature bone with numerous osteocytes, partial degradation of BCP particles, and new bone area fraction >70% in GPCT.”
Animals3.5 mm femoral defectfemur8 weeks
Drug design, development and therapy
Bone mineral density
upin rats1
1 study
Bone mineral density
upin rats1
T-ob/bcp particle/gelma composite increases bone mineral density in 3.5 mm femoral critical-size bone defects.
“In vivo, micro-CT revealed significantly higher BV/TV, Tb.N, Tb.Th, and BMD in the GPCT group versus others.”
Animalsin 3.5 mm femoral critical-size bone defectsfemur8 weeks
Drug design, development and therapy